Hepatocellular proliferation and development of hepatocellular carcinoma: A case-control study in chronic hepatitis C

Human Pathology

Volumn 29, Issue 11, 1998, Pages 1279-1284

  Dutta, Usha ^b   Kench, James ^b   Byth, Karen ^b   Khan, Mahbub H ^b   Lin, Rita ^b   Liddle, Christopher ^b   Farrell, Geoffrey C ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b NONE

Author keywords

Apoptosis; bcl 2; Chronic hepatitis C; Dysplasia; Hepatocellular carcinoma; Ki 67; p53; Proliferation

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; FEMALE; GENE OVEREXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; SCORING SYSTEM;

EID: 0031788913     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90257-X     Document Type: Article

References (45)

1. Szmuness W: Hepatocellular carcinoma and hepatitis B virus: Evidence for a causal association. Prog Med Virol 28:40-69, 1978
2. Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 15:64-69, 1995
3. Kew MC, Popper H: Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 4:136-146, 1984
4. Resnick RH, Koff R: Hepatitis C-related hepatocellular carcinoma. Arch Intern Med 153:1672-1677, 1993
5. Sarasin FP, Giostra E, Hadengue A: Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 171:422-434, 1996
6. Tanaka K, Ikematsu H, Hirohata T, et al: Hepatitis C infection and risk of hepatocellular carcinoma among Japanese: Possible role of type 1b (II) infection. J Natl Cancer Inst 88:742-746, 1996
7. Benvegnu L, Alberti A: Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 41:49S-55S, 1996
8. Silini E, Bottelli R, Asti M, et al: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A case control study. Gastroenterology 111:199-205, 1996
9. Bruno S, Silini E, Crosignani A, et al: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 25:754-758, 1997
10. Brechot C: Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma. Hepatology 25:772-774, 1997
11. Zaman SN, Melia W, Johnson PJ, et al: Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients. Lancet ii:1357-1360, 1985
12. Faccioli S, Chieco P, Gramantieri L, et al: Cytometric measurement of cell proliferation in echo-guided biopsies from focal lesions of the liver. Mod Pathol 9:120-125, 1996
13. Nakamura T, Hayama M, Sakai T, et al: Proliferative activity of hepatocytes in chronic viral hepatitis as revealed by immunohistochemistry for proliferating cell nuclear antigen. HUM PATHOL 24:750-753, 1993
14. Adachi E, Hashimaoto H, Tsuneyoshi M: Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia. Cancer 72:2902-2909, 1993
15. Kawakita N, Seki S, Sakaguchi H, et al: Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde. Am J Pathol 140:513-520, 1992
16. Schaffner F: Structural and functional aspects of regeneration of human liver. Dig Dis Sci 36:1282-1286, 1991
17. Popper H, Acs G: Regulatory factors in the pathologic processes of the liver: Modulators and interacting metabolic networks. Semin Liver Dis 5:191-207, 1985
18. Sherman M, Shafritz DA: Hepatitis B virus and hepatocellular carcinoma: Molecular biology and mechanistic considerations. Semin Liver Dis 4:98-112, 1984
19. Sherlock S: Viruses and hepatocellular carcinoma. Gut 35:828-832, 1994
20. Ballardini G, Groff P, Zoli M, et al: Increased risk of hepatocellular carcinoma development in patients with cirrhosis and high hepatocellular proliferation. J Hepatol 20:218-222, 1994
21. Derenzjni M, Trere D, Oliven F, et al: Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease? J Clin Pathol 46:727-729, 1993
22. Cattoretti G, Becker MHG, Key G, et al: Monoclonal antibodies against recombinant parts of Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin section. J Pathol 168:357-363, 1992
23. Linden MD, Torres FX, Kubus J, et al: Clinical application of morphological and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 97:S4-S13,1992 (suppl 1)
24. Finaly CA, Hinds OW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989
25. Lane DP, Crawford LV: T antigen is bound to host protein in SV40-transformed cells. Nature 278:261-263, 1979
26. Mercer WE, Sheilds MT, Amin M, et al: Negative growth regulation in glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A 87:6166-6170, 1990
27. Ojanguren I, Castella E, Llatjos M, et al: p53 immunoreaction in hepatocellular carcinoma and its relationship to etiologic factors: A fine needle aspiration study. Acta Cytol 40:1148-1153, 1996
28. Raedle J, Roth WK, Oremek G, et al: Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sci 40:2587-2594, 1995
29. Reed JC: bc1-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
30. Zhao M, Zhang N-X, Economou M, et al: Immunohistochemical detection of bc1-2 protein in liver lesions: bc1-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia. Histopathology 25:237-245, 1994
31. Lin R, Schoeman MN, Craig PI, et al: Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust N Z J Med 21:387-392, 1991
32. Lin R, Roach E, Zimmerman M, et al: Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. J Hepatol 23:487-496, 1995
33. Khan MH, Thomas L, Byth K, et al: How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 13:419-426, 1998
34. Craig JR, Peters RL, Edmondson HA: Tumors of the liver and intrahepatic bile ducts. Second series, AFIP Washington, Fascicle 26:136-169, 1989
35. Scheuer PJ: Classification of chronic viral hepatitis: Need for reassessment. J Hepatol 13:372-374, 1991
36. Anthony PP, Vogel CL, Barker LF: Liver cell dysplasia: A premalignant condition. J Clin Pathol 26:217-223, 1973
37. Watanabe S, Okita K, Harada T, et al: Morphological studies of liver cell dysplasia. Cancer 51:2197-2205, 1983
38. Coverdale S, Byth K, Field J, et al: Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 22:1065-1071, 1995
39. Lin R, Dutta U, Kaba S, et al: Effects of hepatitis G coinfection on severity of hepatitis C: Relationship to risk factors and response to interferon treatment. J Gastroenterol Hepatol 1998 13:773-780, 1998
40. Liang TJ, Jeffers LJ, Reddy KR, et al: Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18:1326-1333, 1993
41. Yu MC, Yuan J-M, Ross RK, et al: Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology 25:226-228, 1997
42. Takano S, Yokosuka O, Imazeki F, et al: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 21:650-655, 1995
43. Zhao M, Zhang N-X, Laissue JA, et al: Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia (LCD) and hepatocellular carcinoma (HCC): p53 protein is detectable in small cell LCD, and its expression in HCCs is not related to type and grade. Virchows Arch 424:613-621, 1994
44. Ganne-Carrie N, Chastang C, Chapel F, et al: Predictive score of development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology 23:1112-1118, 1996
45. Borzio M, Bruno S, Roncalli M, et al: Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study. Gastroenterology 108:812-817, 1995